Oral galactose will be given at a dose of 0.2gm/kg/dose twice a day (BID) to a maximum of 15 gm BID for a period of 16 weeks.

Oral galactose will be given at a dose of 0.2gm/kg/dose twice a day (BID) to a maximum of 15 gm BID for a period of 16 weeks.
D-Galactose: Oral galactose will be initiated at a dose of 0.2gm/kg/dose twice daily to a maximum of 15 gm BID for a period of 4 months. The prescribed dose of D-galactose powder will be dispensed to subjects in packets, mixed with 4 ounces of water, and consumed orally.

Galactose

Sex: Female, Male

Region of Enrollment

FSPF is reported in relation to its induction of glomerular albumin permeability (Palb) of isolated glomeruli on a range from 0 to 1, with 0 indicative of normal glomeruli and 1 indicative of injury to the permeability barrier. Results will be considered clinically significant if the following criteria is met in response to oral galactose therapy at week 16: Reduction in FSPF to <0.5 Palb or decrease in FSPF by > 0.3 Palb.

Focal Segmental Glomerulosclerosis Permeability Factor (FSPF)

Results will be considered clinically significant if the following criteria is met in response to oral galactose therapy at week 16. Complete remission is defined as (Urine Protein:Creatinine ratio [UPC] <0.2 g/g). Partial remission is defined as UPC 0.2-2 g/g.

Number of Participants Achieving Complete or Partial Remission at 16 Weeks

Overall Study

Asha Moudgil MD, Professor of Pediatrics

Focal Segmental Glomerulosclerosis

Steroid Resistant Nephrotic Syndrome

Oral galactose will be initiated at a dose of 0.2gm/kg/dose twice daily to a maximum of 15 gm BID for a period of 4 months. The prescribed dose of D-galactose powder will be dispensed to subjects in packets, mixed with 4 ounces of water, and consumed orally.

D-Galactose

Children's National Medical Center

Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome

Effect of Oral Galactose on the Level of Focal Sclerosis Permeability Factor and Proteinuria in Children With Steroid Resistant Nephrotic Syndrome: A Pilot Study

Asha Moudgil

Professor of Pediatrics

Children's National Research Institute

National Kidney Foundation

Oral galactose, 0.2 g/kg/dose twice daily for 28 days

Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor

Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS)

Howard Trachtman MD

principal investigator

Northwell Health

Medical College of Wisconsin

Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5

Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS)and Chronic Kidney Disease Stage 5

Investigator